Date: 2011-01-05
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: arGEN-X (The Netherlands) Eli Lilly (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: arGEN-X has entered into an alliance with Eli Lilly to discover and develop novel therapeutic antibody products against targets submitted by Lilly. arGEN-X will generate novel human monoclonal antibody candidates that act on diverse functional sites on Lilly targets. Lilly will have the option to select the most promising mAb candidates to take forward into preclinical and clinical development and potential commercialization. Lilly has exclusive rights to develop and commercialize mAb-based products discovered in the collaboration. Argen-X will apply its SIMPLE Antibody™ Platform. This platform is based on the active immunisation of outbred Camelids with target antigen to deliver antibodies whose variable regions are virtually identical to those of human antibodies. These variable domains are combined with human constant domains to generate full size, fully human therapeutic antibodies.
Financial terms: arGEN-X will receive license fees and research funding, as well as potential milestone payments. Other financial and deal terms were not disclosed.
Latest news:
